Temasek leads US$85m investment round for gene therapy startup

Singapore

IMMUNE cell gene therapy startup Gracell Biotechnologies has raised US$85 million through a Series B round led by Singapore government investment firm Temasek Holdings.

Also taking part in the financing round were Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji.

Gracell's goal is to develop high-quality, low-cost, easy-to-use cellular gene therapies that bring hope to cancer patients in need, said founder, chairman and CEO William Cao, who previously headed Nasdaq-listed Cellular Biomedicine Gro…